Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 541,300 shares, an increase of 22.7% from the March 31st total of 441,200 shares. Based on an average daily volume of 4,071,600 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on BAYRY. Wolfe Research lowered Bayer Aktiengesellschaft from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, January 30th. Sanford C. Bernstein restated a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th. Finally, Citigroup restated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, February 29th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.
Get Our Latest Stock Analysis on BAYRY
Bayer Aktiengesellschaft Trading Up 0.9 %
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.38 by $0.12. The company had revenue of $12.77 billion during the quarter. Bayer Aktiengesellschaft had a positive return on equity of 17.27% and a negative net margin of 6.31%. As a group, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.
Bayer Aktiengesellschaft Cuts Dividend
The business also recently declared a dividend, which will be paid on Monday, May 13th. Investors of record on Tuesday, April 30th will be issued a $0.0191 dividend. The ex-dividend date is Monday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio (DPR) is -54.88%.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
See Also
- Five stocks we like better than Bayer Aktiengesellschaft
- What is MarketRankā¢? How to Use it
- The 3 Hottest Insiders Buys This Month
- How to Calculate Options Profits
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- What is the FTSE 100 index?
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.